FindTrial
Sign In

Cytokine Hemadsorption in Covid 19 Patients With Bacterial Sepsis

Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04920851
Enrollment
23
Registered
2021-06-10
Start date
2021-06-10
Completion date
2021-07-20
Last updated
2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

INTERLEUKIN 6

Brief summary

In this retrospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

Interventions

DEVICEcytokine hemadsorption

to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.

Sponsors

Derince Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* COVID-19 patients were the available data of laboratory diagnosis of COVID-19 (a positive throat swab nucleic acid test or positive serum COVID-19 specific antibody test), * patients with COVID-19 induced sepsis was detection of bacterial agent in blood or tracheal culture

Exclusion criteria

* below 18 aged * those who did not undergo hemoperfusion

Design outcomes

Primary

MeasureTime frameDescription
interleukin 61 monthlevel of interleukin 6

Countries

Turkey (Türkiye)

Contacts

Primary Contactilke küpeli
ilkeser2004@gmail.com05555485632

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026